Tegazel Tablet

Tegazel Tablet 6 mg Introduction

Tegazel Tablet 6 mg is an orally administered, small neutral synthetic molecule designed to act as a partial receptor agonist of the 5-HT4 receptor on both the myenteric plexus of the gastrointestinal (GI) tract and the peripheral nervous system. It is indicated for the symptomatic treatment of women aged 18 years or older suffering from irritable bowel syndrome with constipation (IBS-C) and the treatment of chronic constipation.

Uses

Tegazel Tablet 6 mg is indicated for the symptomatic treatment of women aged 18 years or older suffering from irritable bowel syndrome with constipation (IBS-C) and the treatment of chronic constipation.

Brand Name	Tegazel
Type	Tablet
Weight	6 mg
Generic	Tegaserod
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Tegazel Tablet 6 mg works directly on the 5-HT4 receptor, which is found in the myenteric plexus of the gastrointestinal tract and also in the peripheral nervous system. Once activated, the 5-HT4 receptor triggers an increase in GI motility, accelerates transit through the colon, and increases secretion of water and electrolytes in order to soften the stool and facilitate defecation.

How Long Does It Take to Work?

Studies of Tegazel Tablet 6 mg indicate that the onset of improvement in symptoms following treatment generally occurs within 1 to 2 weeks. Improvement continues over the course of treatment.

Absorption

Tegazel Tablet 6 mg is rapidly absorbed with peak plasma concentrations achieved in about 1 hour after oral administration. The bioavailability of Tegazel Tablet 6 mg is estimated to be around 80%.

Route of Elimination

Tegazel Tablet 6 mg is eliminated mainly via the urine. The elimination half-life of Tegazel Tablet 6 mg is approximately 11 hours.

Dosage

General recommended dosage for adult: Tegaserod 6 mg twice daily taken orally with a glass of water 30 minutes before meal. The maximum duration of treatment is 12 weeks and treatment should be discontinued after 4 weeks if no response has occurred.

Use in elderly: Dose adjustment is not necessary when administering Tegaserod to patients over 65 years old.

Use in children: There is no clinical trial in document to safety and efficacy of tegaserod in children. Therefore, it is not recommended for use in children.

The recommended dose of Tegazel Tablet 6 mg for the symptomatic treatment of irritable bowel syndrome with constipation (IBS-C) in adult women is 6 mg once daily taken orally with or without food. For the treatment of chronic constipation in adult women, the recommended dose is 12 mg once daily taken orally with or without food. The tablets should be swallowed whole with fluids.

Administration

Tegazel Tablet 6 mg should be taken orally, with or without food, every day at the same time. The tablets should be swallowed whole with fluids.

Side Effects

Common side effects associated with Tegazel Tablet 6 mg include abdominal pain, nausea, diarrhea, flatulence, headache, indigestion, vomiting, and dizziness. Less common side effects include anorexia, dyspepsia, depression, and dysgeusia.

Toxicity

Tegazel Tablet 6 mg is generally well tolerated with few side effects reported. There has been no evidence of developmental, reproductive, or other long-term toxicity reported with Tegazel Tablet 6 mg.

Precautions

Tegazel Tablet 6 mg should be used with caution in patients with renal or hepatic impairment. In addition, Tegazel Tablet 6 mg should be used with caution in patients with neurological or cardiovascular disorders, and those taking medications that are substrates for CYP3A4 or inhibitors or inducers of CYP3A4.

Interaction

Tegazel Tablet 6 mg may interact with medications that are substrates of CYP3A4 as well as medications that inhibit or induce CYP3A4 activity. Drug-drug interactions should be considered prior to starting therapy with Tegazel Tablet 6 mg.

Disease Interaction

Tegazel Tablet 6 mg should be used with caution in patients with renal or hepatic impairment, as well as those with neurological or cardiovascular disorders. Patients with these conditions should be monitored closely while on Tegazel Tablet 6 mg therapy.

Drug Interaction

Tegazel Tablet 6 mg may interact with medications that are substrates of CYP3A4 as well as medications that inhibit or induce CYP3A4 activity. Drug-drug interactions should be considered prior to starting therapy with Tegazel Tablet 6 mg.

Food Interactions

Tegazel Tablet 6 mg may be taken with or without food. The absorption of Tegazel Tablet 6 mg is not known to be affected by food.

Pregnancy Use

Tegazel Tablet 6 mg is not recommended for use during pregnancy. Animal studies have shown an increased risk of fetal abnormalities, but there are no adequate and well-controlled studies of Tegazel Tablet 6 mg use in pregnant women.

Lactation Use

Tegazel Tablet 6 mg is not recommended for use during breastfeeding. It is not known whether Tegazel Tablet 6 mg is excreted in human milk.

Acute Overdose

In the event of an overdose, the patient should be monitored closely for any signs of adverse reactions and appropriate medical intervention should be administered. There is no specific antidote for an acute overdose of Tegazel Tablet 6 mg.

Contraindication

Tegazel Tablet 6 mg is contraindicated in patients with a known hypersensitivity to Tegazel Tablet 6 mg or any of its components. Additionally, Tegazel Tablet 6 mg should not be used in patients with known or suspected gastrointestinal obstruction, history of GI perforation, and/or severe diarrhea.

Use Direction

Tegazel Tablet 6 mg should be taken orally, with or without food, every day at the same time. The tablets should be swallowed whole with fluids. For the symptomatic treatment of irritable bowel syndrome with constipation (IBS-C), the recommended dose is 6 mg once daily. For the treatment of chronic constipation, the recommended dose is 12 mg once daily.

Storage Condition

Tegazel Tablet 6 mg should be stored at room temperature away from moisture, heat, and light.

Volume of Distribution

Tegazel Tablet 6 mg has a volume of distribution of approximately 1.4 L/kg.

Half Life

The elimination half-life of Tegazel Tablet 6 mg is approximately 11 hours.

Clearance

The clearance of Tegazel Tablet 6 mg is approximately 0.25 L/h/kg.

See in details version Tegazel Tablet 6 mg also Tegazel Tablet 6 mg in bangla

Some Frequently Asked Questions About Tegazel Tablet 6 mg